Other languages Athira Pharma, Inc.

Equities

ATHA

US04746L1044

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
2.04 ^USD	+3.55%		+1.49%	-16.05%

Apr. 15	Athira Pharma, Inc. Appoints Javier San Martin, M.D., as Chief Medical Officer	CI
Apr. 11	Athira Pharma, Inc. Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Athira Pharma, Inc. Appoints Javier San Martin, M.D., as Chief Medical Officer	Apr. 15
Athira Pharma, Inc. Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease	Apr. 11
Athira Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22
Athira Pharma, Inc. Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis	Feb. 08
Athira Pharma, Inc. Provides 2024 Clinical Pipeline Outlook	Jan. 08
Athira Pharma, Inc. Announces Hans Moebius Retires as Chief Medical Officer	Jan. 08
Athira Pharma, Inc. Completes Enrollment of Phase 2/3 Lift-AD Clinical Trial of Fosgonimeton in Mild-To-Moderate Alzheimer's Disease	Jan. 03
Athira Pharma, Inc. Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-B-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease	Nov. 15
Athira Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Athira Says Preclinical Results Back Therapeutic Potential of ATH-1105 in ALS; Shares Rise After Hours	23-10-05
Athira Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Athira Pharma, Inc. Appoints Andrew Gengos as Chief Business Officer	23-08-10
Athira Pharma, Inc. Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimerâ€™s Disease	23-07-17
Athira Pharma Names Andrew Gengos CFO	23-05-22
Athira Pharma, Inc. Announces the Appointment of Andrew Gengos as Chief Business Officer	23-05-21
Athira Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Athira Pharma, Inc. Plans to Further Extend the Current OLEX for the Phase 2/3 LIFT-AD and Phase 2 ACT-AD Trials	23-05-11
Athira Pharma, Inc. Presents New Clinical and Preclinical Data at the American Academy of Neurology 2023 Annual Meeting	23-04-25
Athira Pharma Announces Promotion of Kevin Church to Chief Scientific Officer	23-01-31
Athira Pharma Enters Deal With Cantor Fitzgerald, BTIG for At-The-Market Stock Offering	23-01-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Athira Pharma, Inc.

Equities

ATHA

US04746L1044

Other languages

Filters